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dipyridamole stress echocardiography versus perfusion scintigra-
phy. In contrast to Fragasso et al., Astarita et al. used a “state-of-
the-art” atropine protocol, and they in fact observed that dipyrid-
amole sensitivity was raised to 88%. Stress echocardiography
protocols have evolved rapidly in recent years. When the diagnosis
is the target, atropine coadministration should be used. When
prognostic stratification is the reason for testing, a high dose
without atropine, even in hypertensive patients (6), provides
excellent stratification (7).
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REPLY
We are grateful to Dr. Varga for his comments on our report (1),
because his letter gives us the opportunity to further clarify our
opinion. Like others (2), in the past, we have used dipyridamole for
the diagnosis of coronary artery disease, but we (3) have been unable
to reproduce the diagnostic accuracy reported by some groups.
Interestingly enough, the near totality of these data comes from a
single institution. In our study, we decided not to use atropine to
assess the intrinsic strength of the individual stressors. The sensitivi-
ties and specificities for perfusion scintigraphy, dipyridamole and
dobutamine echocardiography were 98% and 36%, 61% and 91%,
88% and 80% respectively. As a consequence, accuracy, which takes in
account both sensitivity and specificity, was not significantly different
between the three tests, although dobutamine appeared to perform
better (84%) than dipyridamole (74%) and scintigraphy (71%). Fur-
thermore, in patients with one-vessel disease, the performance of
dipyridamole was very poor, with a sensitivity of 31%. We do not
think that the addition of atropine could have increased this figure to
an acceptable level, especially if we take into account that, in this
subgroup, the sensitivities of dobutamine and scintigraphy were 85%
and 95%, respectively. Indeed, we believe that such differences are
enough to justify our statement that dobutamine echocardiography (as
well as rest/stress myocardial perfusion scintigraphy) are better than
dipyridamole echocardiography in these patients. We cannot afford
the risk of missing so many patients with coronary artery disease in
such a high-risk group. In addition, this statement is also justified by
pathophysiologic considerations. Dobutamine increases oxygen de-
mand by increasing contractility, heart rate and systolic blood pres-
sure. These features make dobutamine an ideal stressor in hyperten-
sion. In contrast, dipyridamole produces coronary vasodilation, with
little “myocardial stress,” as defined by changes in the rate–pressure
product and a lesser likelihood of causing myocardial ischemia. This
is why dipyridamole yields high sensitivities when used with scintig-
raphy, where perfusion abnormalities are thought to represent areas of
altered blood flow rather than areas of ischemia; however, this is also
why its sensitivity is low when used with echocardiography.
Surely, the addition of atropine improves sensitivity, but it also
leaves misdiagnosed a large proportion of patients with single-
vessel disease. Furthermore, although dipyridamole is considered a
safe test, most patients experience considerable side effects. Ami-
nophylline is administered at the end of the test, and, when
atropine has also been given, sustained sinus tachycardia usually
ensues, causing discomfort and making the duration of the test as
long as dobutamine testing. On the basis of these considerations,
we think that dobutamine provides the best performance for the
diagnosis of coronary artery disease in hypertensive patients (and
beyond). Our feeling (allowed in a letter!) is that most cardiologists
around the world share the same opinion.
Gabriele Fragasso, MD
Division of Cardiology
Istituto Scientifico San Raffaele
Via Olgettina 60
Milano 20132, Italy
E-mail: fragasso.gabriele@hsr.it
PII S0735-1097(00)00660-4
REFERENCES
1. Fragasso G, Lu C, Dabrowski P, Pagnotta P, Sheiban I, Chierchia SL.
Comparison of stress/rest myocardial perfusion tomography, dipyrida-
mole and dobutamine stress echocardiography for the detection of
coronary disease in hypertensive patients with chest pain and positive
exercise test. J Am Coll Cardiol 1999;34:441–7.
2. Dagianti A, Penco M, Agati L, et al. Stress echocardiography: com-
parison of exercise, dipyridamole and dobutamine in detecting and
predicting the extent of coronary artery disease. J Am Coll Cardiol
1995;62:18–25.
3. Margonato A, Chierchia S, Cianflone D, et al. Limitations of dipyrid-
amole-echocardiography in effort angina pectoris. Am J Cardiol 1987;
59:225–30.
Overdosing With Prostacyclin
in Primary Pulmonary Hypertension
Rich and McLaughlin (1) reported excessively high rest cardiac
outputs in 12 of 55 patients with primary pulmonary hypertension
(PPH) treated with intravenous prostacyclin, all of whom had
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follow-up right heart catheterization. As they point out, the
intravenous dosing of prostacyclin, which has been so helpful in
increasing exercise tolerance and prolonging life in patients with
PPH, is complex. The practice has been to maximize dose at the
time of initiation of treatment and then to adjust the dose
according to symptomatology. The average rest cardiac index was
7.4 liters/min per m2 in these patients. They proceeded to reduce
the dose of prostacyclin, on the basis of repeat cardiac output and
hemodynamic measurements, until they reduced the rest cardiac
index to 4.0 liters/min per m2. This resulted in an average dose
reduction of 39%, with virtually no change in pulmonary artery
pressure. They did not report any data on the effect of the dose
reduction on the patients’ exercise performance (e.g., peak oxygen
consumption [V˙O2] or anaerobic threshold), which is obviously the
important question because exercise limitation is the major symp-
tom in these patients.
From the Fick principle for measuring cardiac output, it is
obvious that V˙O2 is a proxy variable of cardiac output. The dose of
the drug that provides the highest peak V˙O2 during exercise is
therefore also the dose that provides the maximally effective cardiac
output response to exercise (2). The maximal cardiac output that
provides effective perfusion to the tissues without developing lactic
acidosis, and therefore is the sustainable level of exercise, is the
anaerobic threshold, a measurement obtained by measuring carbon
dioxide consumption (V˙CO2) concurrently with V˙O2. The oxygen
pulse (V˙O2/heart rate), measured during the same test, is equal to
the stroke volume 3 arteriovenous oxygen difference, and corre-
lates well with stroke volume as measured by the direct Fick
method. The slope of expired volume (V˙E) versus V˙CO2 is
consistently high in patients with PPH, because it reflects hypo-
perfusion to the ventilated lung. Thus, as recently reported by Wax
et al. (3), cardiopulmonary exercise testing provides a valuable
noninvasive marker that can be useful in guiding therapy.
Cardiopulmonary exercise testing provides a comprehensive,
quantitative, noninvasive assessment of cardiovascular and respi-
ratory function. In preliminary studies of sequential cardiopulmo-
nary exercise testing in patients with PPH treated with prostacy-
clin, we found that a maximal benefit is achieved despite increasing
dosage. The failure to improve variables of aerobic function and
ventilatory efficiency in response to exercise logically sets the
optimal dose.
The high rest cardiac output values reported by Rich and
McLaughlin are counter to those expected in patients with PPH,
and therefore the mechanism would be interesting to address.
They attributed the high rest cardiac outputs to increased inotropy
caused by prostacyclin. They did not provide stroke volume
measurements to support this suggestion. The very flushed skin of
these patients suggests another explanation. Perhaps the reduced
systemic resistance decreased left ventricular afterload. This may
decrease pressure in the left atrium below that of the right atrium,
thereby diverting right atrial blood through a foramen ovale. The
blood flow through the foramen ovale is a right to left shunt, but
the high skin blood flow is functionally a left-to-right shunt.
Prostacyclin is not a selective pulmonary vasodilator. It dilates
the systemic circulation as well as the pulmonary circulation.
Because of the pulmonary arteriopathy in PPH, dilation of the
pulmonary circulation is likely to be more limited than that of the
systemic circulation. Thus, if pulmonary vascular disease limits the
ability to further recruit and dilate pulmonary blood vessels beyond
a certain point with an increasing dose, further dosing will just
dilate the systemic circulation with no benefit to the patient. In
fact, the unneeded vasodilation may be detrimental to the patient,
as Rich and McLaughlin suggest.
Karlman Wasserman, MD, PhD
Division of Respiratory and Critical Care Physiology and
Medicine
Harbor-UCLA Medical Center
1000 W. Carson Street
Torrance, California 90507
Ronald Oudiz, MD
Division of Cardiology
Harbor-UCLA Medical Center
1000 W. Carson Street
Torrance, California 90507
PII S0735-1097(00)00662-8
REFERENCES
1. Rich S, McLaughlin VV. The effects of chronic prostacyclin therapy on
cardiac output and symptoms in primary pulmonary hypertension. J Am
Coll Cardiol 1999;34:1184–7.
2. Stringer W, Hansen J, Wasserman K. Cardiac output estimated
non-invasively from oxygen uptake (V˙O2) during exercise. J Appl
Physiol 1997;82:908–12.
3. Wax D, Garofano R, Barst RJ. Effects of long-term infusion of
prostacyclin on exercise performance in patients with primary pulmo-
nary hypertension. Chest 1999;116:914–20.
1996 Letters to the Editor JACC Vol. 35, No. 7, 2000
June 2000:1993–6
